FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Vashington,	D.C.	20549	
-------------	------	-------	--

heck this box if no longer subject
Section 16. Form 4 or Form 5
oligations may continue. See
atmostica 4/h)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  WAGNER CHARLES F JR  (Last) (First) (Middle)						Issuer Name and Ticker or Trading Symbol     VERTEX PHARMACEUTICALS INC /     MA [ VRTX ]      Indee of Earliest Transaction (Month/Day/Year)								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  X Officer (give title below) below)					wner specify	
C/O VERTEX PHARMACEUTICALS						02/06/2024								EVP & Chief Financial Officer						
INCORPORATED					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
50 NORTHERN AVENUE															X Form filed by One Reporting Person  Form filed by More than One Reporting					
(Street)			2210												Perso		ore tna	in One Repo	orting	
BOSTO	BOSTON MA 02210					Rule 10b5-1(c) Transaction Indication														
(City) (State) (Zip)					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.															
		Table	I - Noi	n-Deriva	tive S	Secui	rities	Acq	uired,	Dis	posed of	, or B	Benefi	cially	y Own	ed				
Date			2. Transac Date (Month/Da	Execution Date			Date,	3. Transaction Code (Instr. 8)  4. Securities Acqui Disposed Of (D) (In 5)					Securit Benefic	rities F ficially (I ed Following (I		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
										v	Amount	(A) or (D)		ice	Transa	ction(s) 3 and 4)			(1115411.47)	
Common Stock 02/06/2						2024					5,814(1)	A	1	\$ <mark>0</mark>	49	49,507		D		
Common	Stock			02/06/	2024				A		9,440(2)	A	1	\$ <mark>0</mark>	0 58,947			D		
Common Stock 02/07/2						/2024			A		7,114 <sup>(3)</sup> A		1	\$0 66,061		5,061	D			
		Tal									osed of, onvertib				Owne	d				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed on Date, Day/Year)	Transaction of			6. Date   Expirati (Month/		7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		De Se (In	Price of rivative curity str. 5)		Owner Form Direct or Ind (I) (In	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
Evolanation					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amour or Number of Shares	er						

- 1. Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024.
- $2. \ Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest in installments beginning on 02/10/2024.$
- 3. Restricted stock unit award that vests in installments beginning on 02/17/2025.

## Remarks:

/s/ Christiana Stevenson, Attorney-in-Fact

02/08/2024

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.